

Special Issue

Colorectal Cancer: From Pathophysiology to Novel Therapeutic Approaches 3.0

Message from the Guest Editor

Colorectal cancer (CRC) is one of the most common malignancies worldwide. Therapeutic approaches vary according to tumor location (colonic or rectal) and pTNM stage, the latter representing a main prognostic factor. In spite of the improvement in the early diagnosis and therapy of CRC, several issues are still open. First, the identification of factors associated with a high risk of progression in non-metastatic (pNOMO) CRC still represents a research challenge and means it would be relevant to select patients for adjuvant treatments. Second, in view of the spreading endoscopic resection of CRC, predictors of nodal metastases in pT1 tumors would help in identifying patients needing surgery. Finally, pre-treatment clinical, endoscopic, or histological features able to predict the response of rectal adenocarcinoma to neo-adjuvant chemo-radiotherapy (CRT) would be useful to design tailored therapeutic strategies. The aim of this Special Issue is to provide new insights into prognostic and predictive factors for early or pNOMO CRC, and for locally advanced rectal carcinoma treated with neo-adjuvant CRT. These could be useful to develop individualized treatments.

Guest Editor

Dr. Valeria Barresi

Department of Diagnostics and Public Health, P.le L.A. Scuro, University of Verona, 37129 Verona, Italy

Deadline for manuscript submissions

closed (31 July 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/120694

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).